Skip to main content
Sign In

Cancer Biology Program Students

Hamid Gari

Hamid Gari (Lambert Lab)
Year started the Program:


Why did you choose the Cancer Biology Program at the University of Colorado Anschutz Medical Campus?

Faculty research at UC Denver focuses on highly relevant, cutting-edge topics in translational cancer biology. Many of the projects on campus have real-world applicability, and this is evident by the number of faculty engaging with industry on discovery and development programs for various cancer indications. I was attracted to this caliber of academic research and enjoyed the prospect of directly interacting with an NCI-designated comprehensive cancer center on campus.

In whose labs did you rotate?

Dan Theodorescu, M.D. Ph.D.
Stephen Malkoski, M.D. Ph.D.
Jim Lambert, Ph.D and Scott Lucia, M.D.

What lab did you join and why:
Short description of your project:

My doctoral thesis characterizes a novel oncogenic pathway and co-amplification paradigm that may mediate the malignancy of some invasive, triple negative breast cancers. If successful, my hope is that the thesis 1) will form foundational evidence and rationale for the therapeutic exploitation of this pathway in steroid-receptor negative breast cancer patients and 2) foster scientific appreciation for a new approach to killing cancer cells that takes advantage of highly evolved, dual-purpose cell regulation systems that become aberrant in cancer but yet, retain the ability to induce cellular senescence and/or apoptosis when manipulated pharmacologically.

Where did you attend undergraduate school and what was your major/minor?

Colorado State University Major: Biomedical Sciences and Biochemistry

What (if anything) did you do between undergraduate and graduate school?

I obtained my master’s degree in Bioscience Enterprise at the University of Cambridge, U.K. While there, and immediately following, I worked as a clinical development and late-stage marketing consultant to various Fortune 500 Pharma companies. My work often consisted of reverse-engineering oncology industry trends (from both macro-environmental health economic and clinical perspectives) to design competitive and relevant pivotal clinical trials, as well as broader clinical development program strategies in a given therapeutic area.

School-Affiliated activities/clubs:

I often attend various clinically-oriented symposia and talks on campus that focus on current issues in the treatment of cancer. I think it provides additional context for the work often conducted in a research lab.

Outside Interests:

Spending time with friends, family, and travelling.

What is your favorite thing about Colorado?

The weather and nice people provide a great quality of life.

Contact information:

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.